leadf
logo-loader
viewAvacta Group PLC

Avacta Group: Liverpool School of Tropical Medicine to validate rapid coronavirus test

Scientists will evaluate the performance of a diagnostic test using real patient samples

Avacta Group PLC -

Avacta Group PLC (LON:AVCT) is teaming up with the Liverpool School of Tropical Medicine to clinically validate the rapid saliva-based coronavirus antigen test it is developing with a firm called Cytiva.

Scientists will assess the performance of a diagnostic test using real patient samples.

"I am delighted to have established this collaboration with the Liverpool School of Tropical Medicine,” said Avacta chief executive, Dr Alastair Smith.

“It is an important partnership which provides Avacta with access to patient samples both in the UK and abroad, where the incidence of the disease is currently much higher, to ensure prompt access to a sufficient number of samples for clinical validation.”

Avacta is a pioneer of Affimer technology - proteins that bind to target molecules and perform a similar role to antibodies.

Affimers can be used to detect targets and can easily be formatted for a wide range of applications and can be simply and cost-effectively manufactured.  

Quick facts: Avacta Group PLC

Price: 156.9 GBX

AIM:AVCT
Market: AIM
Market Cap: £392.77 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

BioIndustry Association marks 'golden age of biotech'

Dr Martin Turner who's head of policy and public affairs at the BioIndustry Association tells Proactive London it's a golden age of biotech currently with many more people wanting to get involved and invest in the sector. He says for newcomers to the space it's important they familiarise...

2 weeks, 6 days ago

2 min read